Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
The U.S. Food and Drug Administration (FDA) on Friday approved the cancer medication Enhertu developed by AstraZeneca ( NASDAQ: AZN ) and its Japanese partner Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) for adult patients with HER2-low breast cancer. HER2 is a t...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2022 Q2 earnings call. For further details see: Daiichi Sankyo Company, Limited 2022 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Earnings Conference Call July 29, 2022, 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Wataru Takasaki - Executive Officer, Head, R&D Division Conferen...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said the first patient was dosed in a phase 2 trial of DS-7300 in patients with pretreated extensive-stage small cell lung cancer (SCLC). The study will evaluate the efficacy and safety of two doses (8 mg/kg or 12 mg/kg) o...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) said a U.S. District Court entered judgment on a jury verdict finding that the company and AstraZeneca's ( NASDAQ: AZN ) drug Enhertu infringed Seagen's ( NASDAQ: SGEN ) U.S. patent wil...
The shares of cancer-focused biotech Seagen ( NASDAQ: SGEN ) have lost ~4% in the morning hours Monday to record the biggest intraday loss since May after the Wall Street Journal reported a potential delay for company’s widely expected buyout deal with Merck ( MRK )...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. We are closely watching corporate results to determine the near-term outlook for international equities. How co...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
Growth stocks continued to trail value through challenging macro and market conditions but the magnitude of underperformance has been narrowing, supporting Strategy results. To manage through the myriad uncertainties in the current environment, we continue to rely on secular and struc...
At the ASCO meeting, BioNTech presented phase-1 clinical trial data for its mRNA-based vaccine for pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer. AstraZeneca and Daiichi presented data for the Destiny-Breast04 trial, which tested Enhertu against chemother...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...